eftilagimod alpha,pembrolizumab
immutep,merck
['tacti-002', 'sclc', 'nsclc', 'pdl']
#asco22 tacti-002 is a multinational open label trial with 3 different potential indications. here, part a (n=114) which looks at efti + pembro as 1l therapy in nsclc, no pdl1 selection. primary endpoint rr by irecist (right endpoint / assumptions here?) 
Director of Thoracic Oncology & Developmental Therapeutics @LombardiCancer, Associate Professor @Georgetown University #LCSM #HereWeGo #ITYSL He/Him